Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24051597 | 1.00 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL24051774 | 1.00 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL11453900 | 0.98 | CA1 (0.52) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL31324613 | 0.98 | CA1 (0.52) | CA1CA2CA12CA7CA14 | |
| SCHEMBL29991294 | 0.84 | OPRK1 (0.68) | DRD2DRD3OPRK1 | |
| SCHEMBL4037866 | 0.84 | OPRK1 (0.68) | DRD2DRD3OPRK1 | |
| SCHEMBL15583618 | 0.80 | AHR (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5071675 | 0.79 | PSEN1 (0.46) | DRD2DRD3OPRK1PNMTSLC6A4 | |
| SCHEMBL24387477 | 0.77 | PNMT (0.44) | PNMTSLC6A4KDM1AAADATHTR2A | |
| SCHEMBL24242574 | 0.77 | SLC6A4 (0.47) | PNMTSLC6A4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590087-B2 | Inhibiting USP36 | VALO HEALTH, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4559911-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING THE SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025104411-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119585265-A | Novel heterocyclic compound and pharmaceutical composition for inhibiting autotaxin comprising same | 株式会社次代生物科学 | 2025-03-07 | — | — | CN | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-114222574-B | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-08-22 | — | — | US | disclosed |
| CN-113412113-B | Amino oxazinamides | 豪夫迈·罗氏有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| EP-1937675-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-4861789-A | Dihydro-indene-amine-dihydrooxazoles | BEECHAM GROUP PLC (GB) | 1989-08-29 | — | — | US | disclosed |
| EP-0251453-A2 | Substituted amino-dihydrooxazoles, -thiazoles and -imidazoles, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | CA1 4654/4885CA2 4158/4885CA12 4864/4885 |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | ENPP2, UACA, ITCH | CA1 1578/4885CA2 915/4885CA12 2655/4885 |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | PDE3B, PDE3A, PDE4A | CA1 3117/4885CA2 1032/4885CA12 3179/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | CA1 1016/4885CA2 575/4885CA12 2746/4885 |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | ENPP2, UACA, ACAT2 | CA1 1296/4885CA2 924/4885CA12 2494/4885 |
| US-12590087-B2 | Inhibiting USP36 | USP36, USP39, USP30 | CA1 3869/4885CA2 4525/4885CA12 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.